Vivani Medical

Vivani Medical Inc is a preclinical-stage biopharmaceutical company. The company develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division. The Biopharm Division includes activities from NPM and Vivani Medical Australia Pty Ltd, and the Neurostimulation Division includes activities from Cortigent and its subsidiary in Switzerland.

VANI

News

Health Care

Market-Moving Exclusives

Exclusives

General

Vivani Medical&#39;s NPM-139 semaglutide implant showed steady drug release and nearly 20% weight loss in preclinical studies, supporting long-term weight management.

EXCLUSIVE: Vivani Medical Subdermal Semaglutide Implant Shows 20% Weight Loss In Animal Study, With Potential For Once-Yearly Dosing

Vivani Medical completed enrollment in its LIBERATE-1 trial, testing a six-month GLP-1 implant for weight management. Top-line results are expected by mid-2025.

EXCLUSIVE: Vivani Medical Announces First Implant In Early-Stage Human Study Of GLP-1 Implant For Obesity

Trading Ideas

Vivani Medical plans to spin off Cortigent into a separate public company, aiming to expand neurostimulation technology while focusing on its drug implants.

EXCLUSIVE: Vivani Medical To Spin Off Cortigent Neurostimulation Business To Create Better Focus On Individual Entities And Shareholder Value

Vivani Medical Inc

Vivani Medical Inc Warrants (14/03/2024)

Vanilla Network

Press Releases

Presenting on the Emerging Growth Conference 78 Day 1 on January 15 Register Now

Presenting on the Emerging Growth Conference 78 Day 2 on January 16 Register Now

Vivani Medical Announces Intent to Spin Off Cortigent Neurostimulation Business

Vivani Medical Achieves First Implant and Full Enrollment in the First-in-Human Clinical Trial of GLP-1 Implant NPM-115 in Obese or Overweight Adults

Vivani Medical to Present at the Emerging Growth Conference on March 27, 2025

Presenting on the Emerging Growth Conference 80, Day 1 on March 26 - Register Now

Presenting on the Emerging Growth Conference 80 Day 2 on March 27 Register Now

Vivani Medical Announces Positive Preclinical Weight Loss Data for NPM-139 Semaglutide Implant, with Potential for Once-Yearly Dosing

Financing

Vivani Medical Announces $8.25M Private Placement Equity Financing

Earnings

Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

AEMD

ASPI

ATCH

ATWT

BIXT

BNRG

BVAXF

CBIH

CSE:BIOV

CSE:HG

CSE:PMC

CSE:RUA

CYIO

EGYF

ELRRF

GOVX

HDRSF

HGRAF

IPWR

JAGX

MKTW

MNMRF

NCSM

NZAUF

PLAB

PMCCF

RGBP

SKYH

TSX:ELO

TSX:VGZ

TSXV:HI

TSXV:MNRG

TSXV:RUA

TSXV:XBOT

UCAR

VIOT

XBOTF

Apyx Medical

HeartBeam

CytoSorbents

Daxor

electroCore

EDAP TMS S.A. - American Depositary Shares, each representing One Ordinary Share

Edap TMS

Fonar

Fractyl Health

Hyperfine

Kewaunee Scientific Corporation - Common Stock

Kewaunee Scientific

KORU Medical Systems, Inc. - Common Stock

KORU Medical Systems

Microbot Medical

Monogram Technologies Inc. - Common Stock

Monogram Technologies

Milestone Scientific

Modular Medical

enVVeno Medical Corporation - Common Stock

enVVeno Medical

Orchestra BioMed Holdings, Inc. - Ordinary Shares

Orchestra BioMed Hldgs

Odysight ai

Owlet

Precision Optics Corporation, Inc. - Common stock

Precision Optics Corp

Vicarious Surgical Inc. Class A Common Stock

Vicarious Surgical

Sight Sciences

Sensus Healthcare

JIN MEDICAL INTERNATIONAL LTD. - Ordinary Shares

Jin Medical International

Zynex

HC Wainwright & Co.

ThinkEquity

Comments

Vivani Medical

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga